[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...